Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier

Eun Seok Gil, Jianshu Li, Huining Xiao, Tao Lowe

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

This study describes novel quaternary ammonium β-cyclodextrin (QAβCD) nanoparticles as drug delivery carriers for doxorubicin (DOX), a hydrophobic anticancer drug, across the blood-brain barrier (BBB). QAβCD nanoparticles show 65-88 nm hydrodynamic radii with controllable cationic properties by adjusting the incorporated amount of quaternary ammonium group in their structure. ATR-FTIR studies confirm the complexation between the QAβCD nanoparticles and DOX. QAβCD nanoparticles are not toxic to bovine brain microvessel endothelial cells (BBMVECs) at concentrations up to 500 μg-mL -1. They also do not change the integrity of BBMVEC monolayers, an in vitro BBB model, including transendothelial electrical resistance value, Lucifer yellow permeability, tight junction protein occludin and ZO-1 expression and morphology, cholesterol extraction, and P-glycoprotein (P-gp) expression and efflux activity, at a concentration of 100 μg-mL -1 Some QAβCD nanoparticles not only are twice as permeable as dextran (M w = 4000 g-mol -1) control, but also enhance DOX permeability across BBMVEC monolayers by 2.2 times. Confocal microscopy and flow cytometry measurements imply that the permeability of QAβCD nanoparticles across the in vitro BBB is probably due to endocytosis. DOX/QAβCD complexes kill U87 cells as effectively as DOX alone. However, QAβCD nanoparticles completely protect BBMVECs from cytotoxicity of DOX at 5 and 10 μM after 4 h incubation. The developed QAβCD nanoparticles have great potential in safely and effectively delivering DOX and other therapeutic agents across the BBB.

Original languageEnglish (US)
Pages (from-to)505-516
Number of pages12
JournalBiomacromolecules
Volume10
Issue number3
DOIs
StatePublished - Mar 9 2009
Externally publishedYes

Fingerprint

Cyclodextrins
Ammonium Compounds
Doxorubicin
Nanoparticles
Endothelial cells
Brain
Monolayers
Blood-Brain Barrier
Glycoproteins
Occludin
Tight Junction Proteins
Acoustic impedance
Dextran
Flow cytometry
Confocal microscopy
Cholesterol
Cytotoxicity
Poisons
Complexation
Drug delivery

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biomaterials
  • Polymers and Plastics
  • Materials Chemistry

Cite this

Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. / Gil, Eun Seok; Li, Jianshu; Xiao, Huining; Lowe, Tao.

In: Biomacromolecules, Vol. 10, No. 3, 09.03.2009, p. 505-516.

Research output: Contribution to journalArticle

@article{402e2a1894044402b263ed320bd6833c,
title = "Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier",
abstract = "This study describes novel quaternary ammonium β-cyclodextrin (QAβCD) nanoparticles as drug delivery carriers for doxorubicin (DOX), a hydrophobic anticancer drug, across the blood-brain barrier (BBB). QAβCD nanoparticles show 65-88 nm hydrodynamic radii with controllable cationic properties by adjusting the incorporated amount of quaternary ammonium group in their structure. ATR-FTIR studies confirm the complexation between the QAβCD nanoparticles and DOX. QAβCD nanoparticles are not toxic to bovine brain microvessel endothelial cells (BBMVECs) at concentrations up to 500 μg-mL -1. They also do not change the integrity of BBMVEC monolayers, an in vitro BBB model, including transendothelial electrical resistance value, Lucifer yellow permeability, tight junction protein occludin and ZO-1 expression and morphology, cholesterol extraction, and P-glycoprotein (P-gp) expression and efflux activity, at a concentration of 100 μg-mL -1 Some QAβCD nanoparticles not only are twice as permeable as dextran (M w = 4000 g-mol -1) control, but also enhance DOX permeability across BBMVEC monolayers by 2.2 times. Confocal microscopy and flow cytometry measurements imply that the permeability of QAβCD nanoparticles across the in vitro BBB is probably due to endocytosis. DOX/QAβCD complexes kill U87 cells as effectively as DOX alone. However, QAβCD nanoparticles completely protect BBMVECs from cytotoxicity of DOX at 5 and 10 μM after 4 h incubation. The developed QAβCD nanoparticles have great potential in safely and effectively delivering DOX and other therapeutic agents across the BBB.",
author = "Gil, {Eun Seok} and Jianshu Li and Huining Xiao and Tao Lowe",
year = "2009",
month = "3",
day = "9",
doi = "10.1021/bm801026k",
language = "English (US)",
volume = "10",
pages = "505--516",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier

AU - Gil, Eun Seok

AU - Li, Jianshu

AU - Xiao, Huining

AU - Lowe, Tao

PY - 2009/3/9

Y1 - 2009/3/9

N2 - This study describes novel quaternary ammonium β-cyclodextrin (QAβCD) nanoparticles as drug delivery carriers for doxorubicin (DOX), a hydrophobic anticancer drug, across the blood-brain barrier (BBB). QAβCD nanoparticles show 65-88 nm hydrodynamic radii with controllable cationic properties by adjusting the incorporated amount of quaternary ammonium group in their structure. ATR-FTIR studies confirm the complexation between the QAβCD nanoparticles and DOX. QAβCD nanoparticles are not toxic to bovine brain microvessel endothelial cells (BBMVECs) at concentrations up to 500 μg-mL -1. They also do not change the integrity of BBMVEC monolayers, an in vitro BBB model, including transendothelial electrical resistance value, Lucifer yellow permeability, tight junction protein occludin and ZO-1 expression and morphology, cholesterol extraction, and P-glycoprotein (P-gp) expression and efflux activity, at a concentration of 100 μg-mL -1 Some QAβCD nanoparticles not only are twice as permeable as dextran (M w = 4000 g-mol -1) control, but also enhance DOX permeability across BBMVEC monolayers by 2.2 times. Confocal microscopy and flow cytometry measurements imply that the permeability of QAβCD nanoparticles across the in vitro BBB is probably due to endocytosis. DOX/QAβCD complexes kill U87 cells as effectively as DOX alone. However, QAβCD nanoparticles completely protect BBMVECs from cytotoxicity of DOX at 5 and 10 μM after 4 h incubation. The developed QAβCD nanoparticles have great potential in safely and effectively delivering DOX and other therapeutic agents across the BBB.

AB - This study describes novel quaternary ammonium β-cyclodextrin (QAβCD) nanoparticles as drug delivery carriers for doxorubicin (DOX), a hydrophobic anticancer drug, across the blood-brain barrier (BBB). QAβCD nanoparticles show 65-88 nm hydrodynamic radii with controllable cationic properties by adjusting the incorporated amount of quaternary ammonium group in their structure. ATR-FTIR studies confirm the complexation between the QAβCD nanoparticles and DOX. QAβCD nanoparticles are not toxic to bovine brain microvessel endothelial cells (BBMVECs) at concentrations up to 500 μg-mL -1. They also do not change the integrity of BBMVEC monolayers, an in vitro BBB model, including transendothelial electrical resistance value, Lucifer yellow permeability, tight junction protein occludin and ZO-1 expression and morphology, cholesterol extraction, and P-glycoprotein (P-gp) expression and efflux activity, at a concentration of 100 μg-mL -1 Some QAβCD nanoparticles not only are twice as permeable as dextran (M w = 4000 g-mol -1) control, but also enhance DOX permeability across BBMVEC monolayers by 2.2 times. Confocal microscopy and flow cytometry measurements imply that the permeability of QAβCD nanoparticles across the in vitro BBB is probably due to endocytosis. DOX/QAβCD complexes kill U87 cells as effectively as DOX alone. However, QAβCD nanoparticles completely protect BBMVECs from cytotoxicity of DOX at 5 and 10 μM after 4 h incubation. The developed QAβCD nanoparticles have great potential in safely and effectively delivering DOX and other therapeutic agents across the BBB.

UR - http://www.scopus.com/inward/record.url?scp=65249177710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249177710&partnerID=8YFLogxK

U2 - 10.1021/bm801026k

DO - 10.1021/bm801026k

M3 - Article

VL - 10

SP - 505

EP - 516

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 3

ER -